Estrella Immunopharma (NASDAQ:ESLA) Shares Down 2% – Here’s What Happened

Estrella Immunopharma, Inc. (NASDAQ:ESLA) traded down 2% during mid-day trading on Wednesday . The stock traded as low as $0.9501 and last traded at $0.98. 47,381 shares traded hands during trading, an increase of 20% from the average daily volume of 39,393 shares. The stock had previously closed at $1.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Stock Up 4.8%

The firm has a 50 day simple moving average of $1.26 and a 200-day simple moving average of $1.28. The stock has a market cap of $42.86 million, a P/E ratio of -2.93 and a beta of 0.85.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. On average, equities analysts anticipate that Estrella Immunopharma, Inc. will post -0.39 earnings per share for the current year.

Hedge Funds Weigh In On Estrella Immunopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd raised its position in shares of Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after purchasing an additional 39,099 shares during the period. Marshall Wace LLP bought a new stake in shares of Estrella Immunopharma during the 4th quarter worth about $88,000. Renaissance Technologies LLC boosted its holdings in shares of Estrella Immunopharma by 1,045.7% during the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after buying an additional 111,779 shares during the period. Geode Capital Management LLC grew its stake in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after buying an additional 8,318 shares during the last quarter. Finally, State Street Corp grew its stake in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after buying an additional 20,900 shares during the last quarter. 0.35% of the stock is owned by institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.